Ceftizoxime is a cephalosporin antibiotic.1 Ceftizoxime is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, and S. epidermidis (IC50s = 1.56, ≤0.025, and 0.78 ?g/ml, respectively), as well as clinical isolates of the Gram-negative bacteria E. coli, K. pneumoniae, and P. mirabilis (IC50s = 0.1, ≤0.025, and ≤0.025 ?g/ml, respectively). It is protective against S. aureus, E. coli, P. mirabilis, or P. vulgaris infection in mice (ED50s = 4.03, 0.02, 0.255, and 0.038 mg/kg, respectively).2 Formulations containing ceftizoxime have been used in the treatment of a variety of bacterial infections.
1.Kamimura, T., Matsumoto, Y., Okada, N., et al.Ceftizoxime (FK 749), a new parenteral cephalosporin: In vitro and in vivo antibacterial activitiesAntimicrob. Agents Chemother.16(5)540-548(1979) 2.Nishida, M., Kamimura, T., Okada, N., et al.Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibioticsJ. Antibiot. (Tokyo)32(12)1319-1327(1979)